These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 11032590)

  • 1. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations.
    Avril N; Rosé CA; Schelling M; Dose J; Kuhn W; Bense S; Weber W; Ziegler S; Graeff H; Schwaiger M
    J Clin Oncol; 2000 Oct; 18(20):3495-502. PubMed ID: 11032590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of primary breast carcinoma with a dedicated, large-field-of-view FDG PET mammography device: initial experience.
    Rosen EL; Turkington TG; Soo MS; Baker JA; Coleman RE
    Radiology; 2005 Feb; 234(2):527-34. PubMed ID: 15671006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis.
    Avril N; Menzel M; Dose J; Schelling M; Weber W; Jänicke F; Nathrath W; Schwaiger M
    J Nucl Med; 2001 Jan; 42(1):9-16. PubMed ID: 11197987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different biological and prognostic breast cancer populations identified by FDG-PET in sentinel node-positive patients: results and clinical implications after eight-years follow-up.
    Agresti R; Crippa F; Sandri M; Martelli G; Tagliabue E; Alessi A; Pellitteri C; Maccauro M; Maugeri I; Barbara P; Rampa M; Moscaroli A; Ferraris C; Carcangiu ML; Bianchi G; Greco M; Bombardieri E
    Breast; 2014 Aug; 23(4):334-40. PubMed ID: 24485802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Value of fused 18F-FDG PET/CT images in predicting efficacy of neoadjuvant chemotherapy on breast cancer].
    Li D; Chen JH; Wang J; Ling R; Yao Q; Wang L
    Ai Zheng; 2007 Aug; 26(8):900-4. PubMed ID: 17697556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standardized uptake value of ¹⁸F-fluorodeoxyglucose positron emission tomography for prediction of tumor recurrence in breast cancer beyond tumor burden.
    Ahn SG; Park JT; Lee HM; Lee HW; Jeon TJ; Han K; Lee SA; Dong SM; Ryu YH; Son EJ; Jeong J
    Breast Cancer Res; 2014; 16(6):502. PubMed ID: 25551703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer.
    Schelling M; Avril N; Nährig J; Kuhn W; Römer W; Sattler D; Werner M; Dose J; Jänicke F; Graeff H; Schwaiger M
    J Clin Oncol; 2000 Apr; 18(8):1689-95. PubMed ID: 10764429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual time point FDG-PET/CT imaging... Potential tool for diagnosis of breast cancer.
    Zytoon AA; Murakami K; El-Kholy MR; El-Shorbagy E
    Clin Radiol; 2008 Nov; 63(11):1213-27. PubMed ID: 18929039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma.
    Hogan MP; Goldman DA; Dashevsky B; Riedl CC; Gönen M; Osborne JR; Jochelson M; Hudis C; Morrow M; Ulaner GA
    J Nucl Med; 2015 Nov; 56(11):1674-80. PubMed ID: 26294295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The correlation of
    Qu YH; Long N; Ran C; Sun J
    Clin Transl Oncol; 2021 Mar; 23(3):620-627. PubMed ID: 32683540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicentric study on ¹⁸F-FDG-PET/CT breast incidental uptake in patients studied for non-breast malignant purposes.
    Bertagna F; Evangelista L; Piccardo A; Bertoli M; Bosio G; Giubbini R; Orlando E; Treglia G
    Rev Esp Med Nucl Imagen Mol; 2015; 34(1):24-9. PubMed ID: 25312053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy of 18F-FDG PET/CT for primary tumor visualization and staging in T1 breast cancer.
    Koolen BB; van der Leij F; Vogel WV; Rutgers EJ; Vrancken Peeters MJ; Elkhuizen PH; Valdés Olmos RA
    Acta Oncol; 2014 Jan; 53(1):50-7. PubMed ID: 23672678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer.
    Crippa F; Agresti R; Seregni E; Greco M; Pascali C; Bogni A; Chiesa C; De Sanctis V; Delledonne V; Salvadori B; Leutner M; Bombardieri E
    J Nucl Med; 1998 Jan; 39(1):4-8. PubMed ID: 9443729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of FDG-PET/CT at the postoperative surveillance in the breast cancer patients.
    Jung NY; Yoo IR; Kang BJ; Kim SH; Chae BJ; Seo YY
    Breast Cancer; 2016 Jan; 23(1):141-148. PubMed ID: 24872087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial Results of a Prospective Clinical Trial of 18F-Fluciclovine PET/CT in Newly Diagnosed Invasive Ductal and Invasive Lobular Breast Cancers.
    Ulaner GA; Goldman DA; Gönen M; Pham H; Castillo R; Lyashchenko SK; Lewis JS; Dang C
    J Nucl Med; 2016 Sep; 57(9):1350-6. PubMed ID: 26940766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
    Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
    Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Significance of 18F-FDG-PET in Invasive Lobular Carcinoma.
    Fujii T; Yajima R; Kurozumi S; Higuchi T; Obayashi S; Tokiniwa H; Nagaoka R; Takata D; Horiguchi J; Kuwano H
    Anticancer Res; 2016 Oct; 36(10):5481-5485. PubMed ID: 27798919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Diagnostic and therapeutic impact of 18F-FDG-PET/CT in patients with suspected breast cancer recurrence].
    Palomar Muñoz A; García Vicente AM; Talavera Rubio MP; Pilkington Woll JP; Poblete García VM; Bellón Guardia ME; León Martín A; Cordero García JM; Soriano Castrejón A
    Rev Esp Med Nucl; 2010; 29(3):100-8. PubMed ID: 20392542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.